Mark Richie Malate
About Mark Richie Malate
Mark Richie Malate is a Project Analyst at Scapa Healthcare in Gargrave, England, where he has worked since 2021. He holds an MSc in Microbiology and a BSc (Hons) in Forensic Biology from Teesside University.
Work at Scapa Healthcare
Mark Richie Malate has been employed as a Project Analyst at Scapa Healthcare since 2021. In this role, he is based in Gargrave, England, United Kingdom. His responsibilities include analyzing project data and contributing to the development of healthcare solutions. His tenure at Scapa Healthcare has lasted for three years, during which he has gained experience in project management within the healthcare sector.
Education and Expertise
Mark Richie Malate holds a Master of Science (MSc) in Microbiology from Teesside University, which he completed in 2020. Prior to that, he earned a Bachelor of Science with Honours (BSc Hons) in Forensic Biology with Professional Experience from the same institution, graduating in 2019. His educational background provides him with a strong foundation in microbiology and forensic science, contributing to his analytical skills in his current role.
Professional Background
Before joining Scapa Healthcare, Mark Richie Malate worked as a Microbiology Laboratory Technician at ALS Food & Pharmaceutical UK for seven months in 2020 to 2021. His role involved conducting microbiological testing and analysis. Additionally, he served as a Forensic DNA Analyst at Eurofins Forensic Services for one year from 2017 to 2018 in Risley, Cheshire, United Kingdom, where he was responsible for DNA analysis in forensic investigations.
Career Progression
Mark Richie Malate's career has progressed through various roles in the fields of microbiology and forensic science. His experience as a Forensic DNA Analyst and a Microbiology Laboratory Technician has equipped him with practical skills that he applies in his current position as a Project Analyst at Scapa Healthcare. His educational qualifications and work history reflect a commitment to the life sciences and healthcare industries.